Rockville, MD – BioHealth Innovation, Inc. (BHI) is proud to announce that our Founder, President & CEO, Rich Bendis, has been named a finalist for the Community Builder Award in the 2023 BioHealth Capital Region Annual Awards, hosted by BioBuzz.

Rich Bendis’ dedication to fostering innovation and supporting the biohealth ecosystem has been instrumental in driving growth and collaboration within the industry. His visionary leadership at BHI has created a platform for emerging companies, researchers, and entrepreneurs to connect with resources, expertise, and opportunities, significantly contributing to the region’s economic development and public health advancements.

BioBuzz’s recognition of Rich Bendis as a finalist for the Community Builder Award is a testament to his unwavering commitment and impactful work in the BioHealth Capital Region, encompassing Maryland, Washington, DC, and Virginia.

With the LSN Digital RESI Conference approaching quickly, Event Gold Sponsor, BioHealth Innovation (BHI), is stepping up to help lead five panels with some heavy hitters from the BioHealth Capital Region (BHCR) on June 8-10, 2020.

Great Investment Opportunities in the BioHealth Capital Region

While we adjust to a COVID-19 world, there continue to be great investment opportunities in the BioHealth Capital Region. Join BHCR CEOs as they make short introductions about themselves and companies. Join CEOs from American Gene Technologies International Inc., miRecule, Adaptive Phage, Healion Bio, KaloCyte, Emocha, Tailored Therapeutics, Inc., DEKA, and Ashvattha Therapeutics, Inc.

We are excited to announce that Rich Bendis of BioHealth Innovation will be the keynote speaker at the 2019 Technology Showcase. Now in its third year, the Technology Showcase promises to be a "must attend" event for biotech stakeholders in Maryland/DC/VA region. Check out the event page to learn more about our keynote speaker and some of the great panel sessions that we have planned.

Make sure to reserve time on your calendar for the afternoon of Wednesday, June 12.

The 2019 Technology Showcase is a half-day event that will showcase technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNLCR) to encourage startup company formation, technology licensing and collaborations. Innovators, entrepreneurs, investors and business development professionals should attend. 

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW:  https://tinyurl.com/BHISBIR2019

• 8:00 a.m. – Networking and Registration
• 8:30 a.m. – Welcome
• 8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging
  • National Institute on Drug Abuse
  • National Cancer Institute  
• 9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab  
• 10:00 a.m. – BREAK
• 10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation    
• 11:00 a.m. – BREAK  
• 11:15 a.m. – SBIR Funding Opportunities with USAMRC    
• 11:45 a.m. –  Lunch  
• 12:45 p.m. – (1:1 Room Set)  
• 1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
• 1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)  
• 2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)  
• 2:30 p.m. –  Writing Your Phase II Commercialization Plan  OR 1:1 Meetings* (available simultaneously))  
• 3:00 p.m. –  1:1 Meetings* (NIH only)  
• 4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019
No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.

• How do you obtain coverage and payment for your technology?
• Is the process different for medical devices from diagnostics or therapeutics?
• Can digital apps be reimbursed?
• How do I work with bundled payments?
• What is the process for securing reimbursement codes?  Do I need different strategies based upon the point of care?
• How much do I need to budget for a reimbursement strategy?  When do I need one?
• How to I talk to investors about my reimbursement strategy? 

Learn the answers to these questions and more through the November 14^th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 11/13 is required).

• 8:15 a.m. Networking and Coffee
• 8:30 a.m.  – Issues Overview (in person/by videoconference)
  • Speakers:  Brian Abraham, Founder, Lara Reimbursement Advisory
  • Luis Gutierrez, Entrepreneur-in-Residence, NHLBI and BioHealth Innovation
• 9:30 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, TEDCO and Montgomery County. It is open to anyone in the BioHealth Capital Region.  

To register/For more information, email:  BHI@BioHealthInnovation.  (In person 1:1 scheduling:  www.tinyurl.com/BHIappointments.)

*Attendance at Overview in person/by videoconference required to participate in 1:1 sessions.

To foster development, production and marketing of the next generation of medical devices designed to meet growing children’s unique needs, the Food and Drug Administration (FDA) awarded $5 million to the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), led by Children’s National Health System and University of Maryland, College Park. New Consortium members include BioHealth Innovation, Inc., a Maryland-based innovation intermediary that supports the transformation of research projects into new business opportunities, and MedTech Innovator, a California-based virtual startup accelerator that matches health care industry leaders with early-stage and emerging growth medtech companies for mentorship and support. NCC-PDI’s affiliated members include industry leaders such as Smithwise, Epidarex, and Cadence. 

Welcome to the 2018 BioHealth Capital Region Forum: State of the BioHealth Capital Region's EcoSystem

Presented by: Rich Bendis, President & CEO, BioHealth Innovation Inc.

BioHealth Innovation, Inc. (BHI) has received the International Business Innovation Association (InBIA)’s January 2018 IMPACT Award in Biotech/Cleantech for the management of four spaces for early stage companies: the Germantown Innovation Center, the Rockville Innovation Center, LaunchLabs, and the BHI International Innovation Center.   The award is based on a variety of metrics including affiliations and partnerships, application and graduation, facilities, mission and goals.  This recognition also enables this innovation activity to be considered with other leading entrepreneurial centers across the country as a finalist for the InBIA’s annual Incubator of the Year Awards.  

MCEDC talks with Rich Bendis, President and CEO of BioHealth Innovation, about how his organization fuels the science industry in Montgomery County, Maryland.

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil® (Anthrax Immune Globulin Intravenous [human]) to the Canadian government. This contract award follows the recent approval of Anthrasil by Health Canada under the Extraordinary Use New Drug (EUND) Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible. Anthrasil is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.

That Indians are not only heading global IT giants like Google and Microsoft but also a number of startups in diverse sectors, including biotechnology, across the US is evident from the fact that of the 52 companies operating out of the two innovation hubs in Rockville and Germantown in Maryland 11 are either headed or run by Indians.

From mobile technology platform connecting doctors and patients to pre-market cybersecurity for IoT (Internet of Things) devices, Indian Americans are the driving force behind several firms at the two innovation hubs managed by BioHealth Innovation, Inc, a non-profit public-private partnership, which aids early stage biotechnology companies from research to commercialization.

In 2010, an industry-led task force created in Montgomery County partnered with members of regional academia, government and other nonprofits to create an entrepreneurial innovation ecosystem that wasn’t being filled.

BioHealth Innovation Inc. (BHI), which was founded in 2012 by Richard Bendis in Rockville, Md., is designed to help bio-health companies grow, identify commercially relevant science, create new businesses and attract equity funding to the region. Bendis, who is also the president and CEO, has overseen the organization’s creation of unique programming for entrepreneurs at the National Institutes of Health, the University of Maryland and Johns Hopkins University.

Robust private-sector investment and prudent regulation from policymakers have helped establish Maryland as a cradle of innovation and a leader in the U.S. innovation economy. Few states can match Maryland's highly skilled workforce, market access and technology-centered policy incentives, and the U.S. Chamber of Commerce ranked Maryland No. 1 in the country for entrepreneurship and innovation.

But continued leadership of the region — and the ability of the region to continue to reap the economic and jobs benefits of innovation — is not a given. It requires constant cultivation and smart action from our elected officials.

Maryland is home to more than 800 life sciences companies, 70 federal labs and 16 colleges and universities, including National Institutes of Health, the Food and Drug Administration, Johns Hopkins University, the University System of Maryland and companies like MedImmune and GlaxoSmithKline. About 6 percent of Maryland's gross domestic product — $17.6 billion — is generated by the life sciences, and the biotechnology industry in Maryland alone employs about 34,000.

During the most recent legislative session in Maryland, the General Assembly considered a piece of onerous drug pricing legislation that threatened the biopharmaceutical ecosystem in the state while also potentially impeding access to care for Maryland patients.

In the name of "transparency," the legislation — which would have been the most hostile to industry in the country — imposed complex bureaucratic reporting requirements that disregarded the extraordinary development requirements and complex distribution channels for innovative drugs and therapies.

Read more via the Capital Gazette

The Daily Record has named BioHealth Innovation Inc., (BHI) President and CEO Richard Bendis a 2017 Influential Marylander. Mr. Bendis is one of 51 Influential Marylanders who were selected by the publication for their significant contributions to their respective fields and leadership in the state.

“It’s an honor to be chosen as an Influential Marylander by The Daily Record. BHI has been working with our partners and other key stakeholders to help make Maryland a leader in the BioHealth Capital Region,” said Mr. Bendis. “Our success in supporting over 800 companies, scientists, and entrepreneurs since 2012 is a testament to the hard work and dedication of the entire BHI team.”

Mr. Bendis, along with the other Influential Marylanders, will be presented their awards on March 23, 2017 at a reception and dinner at The Grand Lodge of Maryland. The winners will also be profiled in a special magazine that will be inserted into the March 24^th issue of The Daily Record and available online at www.TheDailyRecord.com.

"Influential Marylanders help to shape their communities – our communities – for the better. They are at the pinnacle of their chosen professions and are role models for all of us," said Suzanne Fischer-Huettner, publisher of The Daily Record. "Their hard work, determination and commitment to excellence help us to realize our own hopes and dreams. The Daily Record is honored to recognize their accomplishments."

About BioHealth Innovation, Inc.

BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. BHI is known for providing commercial assistance to scientists and founders, educating and infusing Maryland's life science community with new and young entrepreneurs and fueling startups within Central Maryland's bio-ecosystem by connecting young companies to funding and business resources. Learn more at: www.biohealthinnovation.org

Click here to view all of the 2017 Influential Marylanders Honorees.

BioHealth Innovation inked a pair of recent deals to run incubators in Montgomery County.

The Rockville-based organization that works to help health and life sciences startups in the region is set to manage the Germantown Innovation Center and the Rockville Innovation Center. It’s the first foray into running incubators for the public-private partnership, which also helps startups coming out of UMB and Johns Hopkins in Baltimore.

Rich Bendis was a speaker at the BioHealth Capital Region Forum last week to discuss the state of the BioHealth industry in the capital region and benchmark our region against the top regions in the United States.

View Presentation

Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001).  Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company's preclinical pipeline.

Today, U.S. Secretary of Commerce Penny Pritzker announced the 25 awardees that will receive $10 million under the Economic Development Administration’s (EDA) 2015 Regional Innovation Strategies (RIS) program. The 2015 RIS program is managed by EDA’s Office of Innovation and Entrepreneurship (OIE) and is designed to advance innovation and capacity-building activities in regions across the country through two different competitions: the i6 Challenge and the Seed Fund Support (SFS) Grants competition.

“As the driving force behind the Administration’s focus on entrepreneurship, the Department of Commerce is committed to helping set the conditions for innovators and entrepreneurs to test new ideas, take risks, find financing and customers, and ultimately thrive,” said Secretary Pritzker. “The Regional Innovation Strategies program is critical to ensuring that entrepreneurs have access to the tools they need to move their ideas and inventions from idea to market.”

Hear from the exciting companies completing the first Relevant Health cohort! This event is currently invite only, but if you would like to find out more and possibly attend please send an email to This email address is being protected from spambots. You need JavaScript enabled to view it.

To find out more about the cohort, click here!

Sixteen leaders from key federal, academic and industry organizations have been appointed by Governor Larry Hogan to the Maryland Life Sciences Advisory Board (LSAB).

The new appointees include a patient advocate, executives from global life sciences companies with U.S. headquarters in Maryland, small biotechnology companies, and leaders from the University of Maryland, University of Maryland Baltimore, Johns Hopkin University, Montgomery College, NIH, FDA and the U.S. Army Medical Research and Material Command.

The D.C. area is home to a number of great startup accelerators that can really make a difference for young companies. The right program can provide the resources and advice that entrepreneurs need to transform what may be a great idea into a viable product and thriving startup. Check out a few of the newer and vertical-specific accelerator programs in the D.C. area that you should keep an eye on in 2016.

BioHealth Innovation, Inc. would like to welcome Ellen Raines, the newest addition to our team! She is responsible for supporting the CEO, interacting with industry and academic institution leaders, as well as local, state and federal government officials and staff. Ellen has over 10 years of executive assistant experience with local and bioscience companies. She lives in Gaithersburg with her two teenage children and spends her free time supporting her children’s sports teams and events, teaching Pilates, swimming, biking, golfing and enjoys cooking for family and friends.

A new health technology accelerator is looking for applicants for its five month program.It is the latest in a steady growth of organizations helping entrepreneurs navigate the long sales cycle and other unique challenges healthcare industry startups face.

Relevant Health, based in Rockville, Maryland, was formed through a partnership between BioHealth Innovation, Montgomery County’s Economic Development department and Product Savvy, which will run the day-to-day operations.

BHI issued a Commercial Relevance Award to three companies as part of the Invest Maryland Challenge, Maryland's statewide business plan competition. The three companies each offer a differentiated product or service to the biohealth marketplace with an opportunity to provide significant commercial value to the health industry granting the the Commercial Relevance title..

Sickweather is a Batimore-based health information company that scans social networks for indicators of illness, allowing you to check for the chance of sickness as easily as you can check for the chance of rain.

Care Progress is a Bethesda-based company with a software platform to efficiently manage and treat cancer patients at home and maximize reimbursement through outcomes-based care management.

Tissue Analytics is a Johns Hopkins University spin-out that is transforming the common smartphone into a sophisticated medical imaging system.
BHI will offer strategic consulting services with selected companies to support the growth of these businesses and doe do using our knowledge, network and process for assisting early-stage biohealth companies. BHI is pleased to continue to partner with the State of Maryland's Invest Maryland Challenge to support the growth of emerging biohealth businesses.

New for 2015! BHI's Funding Newsletter provides a monthly snapshot of biohealth funding opportunities from federal, state, local government, and private sources that could be relevant to advance your small business. BHI's goal is to assist companies determine feasible non-dilutive funding pathways or government contract opportunities to enable biohealth businesses at multiple stages of development.

Please contact our Federal Funding Assistance program when seeking support for any of the opportunities.

Recent winners: Perceptive Navigation wins Phase II SBIR

A new business accelerator dedicated to health technology startups is launching this fall in Montgomery County's Rockville Innovation Center. Led by health and life sciences consortium BioHealth Innovation Inc., eight startup companies with health tech ideas will be selected to begin the five-month acceleration program called "Relevant Health." The program is part of a partnership with Montgomery County's Department of Economic Development and will begin in September.

The story of MedImmune, the Maryland startup that British pharmaceutical giant AstraZeneca bought for $15.6 billion in 2007, is an example for entrepreneurs striving for their own blockbuster deals. But MedImmune leaders say they want to go beyond leading by example.

MedImmune taps federal institute for research partnership The company, now responsible for half of AstraZeneca's pipeline of drug candidates, has signed a flurry of partnerships with federal and nonprofit labs in recent months, including deals to share resources and researchers with the National Cancer Institute, the National Institute of Standards and Technology and the Joslin Diabetes Center at Harvard University. Through the partnerships, the company can tap the labs' brainpower and expensive equipment, and share its own resources.

The Montgomery County Department of EconomicDevelopment (MCDED) is pleased to announce the recipients of the 2015 Life Sciences Impact Grant Awards. The program, introduced in December of 2014, was created to provide financial assistance to life sciences employers to retain jobs and stimulate the organic growth of the life sciences industry in Montgomery County.

"The county is committed to supporting the innovation economy,” commented Sally Sternbach, Acting Director, Department of Economic Development. “The Life Sciences Impact Grant is just one example of the comprehensive portfolio of programs that make up the MC Squared initiative."

Tao Yu, a graduate student in the Department of Biomedical Engineering, talks about his internship with Biohealth Innovation, through the Johns Hopkins University School of Medicine's Biomedical Careers Initiative (BCI).

View the interview here.

Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc. and will focus solely on the business of Pieris AG, a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The share exchange transaction was effected on December 17, 2014, and beginning on December 18, 2014, Pieris will trade under the symbol "PIRS" on the OTC Markets.

– BHI Entrepreneurs-in-Resident Help Drive Client Progress –

ROCKVILLE AND BALTIMORE, MARYLAND, December 16, 2014 – BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced recent highlights of funding achievements for clients, BeneVir Biopharm, Inc., and Perceptive Navigation, LLC. The significant progress poises both companies for clinical and/or commercial advancement in 2015.

BeneVir Biopharm, recently announced that it closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (OTCQB: HCHC). BeneVir is a Maryland-based company founded in 2011. Based on technology developed by New York University, BeneVir is developing an advanced immunotherapeutic platform for the treatment of solid tumors that can both directly kill tumor cells and also activate the human immune system to target tumor metastases and prevent recurrence of tumors. Currently, the company is focused on advancing its lead program into human trials for ovarian, breast, and bladder cancer. BHI’s Entrepreneur-in-Residence Ram Aiyar, Ph.D., worked as a member of the BeneVir team to enhance the commercial potential of the company by building novel intellectual property, expanding the therapeutic pipeline and identifying potential development partners.

Noble Life Sciences (Gaithersburg, MD), a provider of preclinical drug development services, today announced the acquisition of Spring Valley Laboratories (Sykesville, MD), a full service, GLP (Good Laboratory Practice)-compliant, preclinical contract research organization (CRO) for the development of drugs, vaccines, and medical devices.   

The acquisition greatly expands Noble’s services to include GLP regulatory standards, studies in small and large animals, and testing capabilities for vaccines and medical devices. Combined with Noble’s recognized strength conducting studies directed at early-stage products, the acquisition of Spring Valley Laboratories extends the Company’s suite of offerings across the full continuum of preclinical studies from initial product discovery through regulation-compliant studies for submission to FDA and other similar agencies.